23 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
at the American Society of Hematology (ASH) Annual Meeting.
R&D Highlights
C3 glomerulopathy (C3G) and immune complex glomerulonephritis (IC-MPGN … the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of C3G and IC-MPGN at the American Society of Nephrology
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
submits all reported adverse events to the U.S. FDA consistent with reporting guidelines for drug manufacturers. Apellis and the American Society of Retina
8-K
EX-99.1
q7d8ki7yxvce2a8sb5q
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
03ft5zava1zwbw6f
17 Jul 23
Regulation FD Disclosure
4:14pm
424B5
r01gzc 54nj9sl
9 Jan 20
Prospectus supplement for primary offering
5:25pm
424B5
fim1 crdpqs
7 Jan 20
Prospectus supplement for primary offering
4:19pm
424B5
1610be s96y0ccjt8
7 Mar 19
Prospectus supplement for primary offering
4:28pm